A new drug has been approved for obstructive hypertrophic cardiomyopathy (HCM); Oklahoma enacts a strict abortion ban; whistleblower claims alarms had been raised about Abbott baby formula contamination.
The FDA has approved Bristol Myers Squibb’s treatment mavacamten for adults with obstructive hypertrophic cardiomyopathy (HCM), making it the first and only approved drug to target the underlying pathophysiology of the condition, according to a company statement. The oral treatment received approval for 2.5-mg, 5-mg, 10-mg and 15-mg capsules and is only indicated for those with New York Heart Association (NYHA) class 2-3 obstructive HCM. Mavacamten is also the only approved cardiac myosin inhibitor for use in the country, Reuters reports. Obstructive HCM is a common cause of cardiac arrest in young people and affects around 1 in 500 individuals in the United States.
Oklahoma’s legislature approved a bill yesterday that prohibits abortion after 6 weeks of pregnancy that will go into effect as soon as it’s signed into law by Governor Kevin Stitt, The Washington Post reports. The state is already popular with those from neighboring Texas seeking the procedure who are limited by that state’s own controversial bill. The Oklahoma bill makes exceptions for medical emergencies but not for cases of rape or incest. Stitt is expected to sign the bill, while an additional bill voted on by the state’s senate seeks to ban abortions at all stages of pregnancy, with exceptions for rape, incest, and medical emergencies. This bill will next move to the House.
According to reporting by CNN, a complaint shows a whistleblower alerted the FDA to alleged safety lapses at a plant that produced baby formula months before recalls of the formula began. The complaint came from a former employee at Abbott Nutrition who said the company was hiding safety problems at its Michigan plant. In February, the company recalled 3 brands of powdered infant formula after infections from Cronobacter sakazakii bacteria were reported. Two infants died and production at the plan remains paused. In the whistleblower compliant, the former employee said he saw records falsified and a lack of disclosure of information. It also states the employee was fired after raising the safety concerns.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More